After months of hard work developing your SBIR proposal, there’s nothing quite as disappointing as having a few preventable errors keep your application from getting reviewed.
Recently, the NIH’s Center for Scientific Review (CSR) published their “Top 10 Submission Show Stoppers for NIH Small Business Applicants – SBIRs.” At FreeMind, we took a look at the top CSR preventable errors and suggested how to best tackle these ahead of time.
- Not Having Multiple Registrations in Place: The SBIR/STTR application process requires five. Your application needs to pass through the government-wide portal (Grants.gov). To do this, your company needs an active System for Award Management (SAM) account, which expires after 12 months. To get this account, your company needs a DUNS number, a Taxpayer Identification Number (TIN), and a CAGE code. Getting these numbers and having an active account can take up to 8 weeks. Complete these registrations early so you and your collaborators can be ready on submission day. You and your institution also need separate NIH eRA Commons registrations.
FreeMind: The CSR is entirely correct that proper registration is vital to submission, you can’t technically submit without this. However, they have overlooked another required registration to the SBA. A downloadable PDF is actually required from that site in your application package.
- Failing to Appreciate the Fact that Submission Is a Multi-Step Process: Your application must pass through Grants.gov and then through the NIH eRA system. These systems have separate checks/validations. If your application is stopped at Grants.gov, be sure to alert both help desks immediately. After eRA acceptance, NIH staff performs additional, manual compliance checks.
FreeMind: This is correct, and exactly why you should aim at submitting ahead of time. The helpdesks can indeed be very helpful, and make sure to keep your ticket number for later reference. One item of note here is that the new submission system for the NIH “ASSIST” does the compliance error checks before submission, which does save a little time. *This isn’t relevant if submitting via PDF package.
- Submitting Your Application at the Last Minute: Electronic submission errors can take hours to fix. Give yourself peace of mind and submit early—days, not hours or minutes! Only error-free applications submitted on time can be sent forward to reviewers.
FreeMind: Not much to say here except to enthusiastically agree. You’ll be doing yourself a favor by planning and managing your time correctly, targeting a 24-48 hour pre-deadline submission.
- Attempting to Fix a Warning after the Deadline: Warnings are not show stoppers. Your application will be accepted with a warning. But if you seek to fix a warning after the submission deadline by rejecting your application and submitting a corrected one, your application will be late and will not go forward.
FreeMind: This is a technical point, and a fine one to be made. There are very few [acceptable] reasons to submit after the deadline. And, if you already had your application in the system, there’s no acceptable reason to submit a correction after the deadline. Errors must be fixed (if not using ASSIST), but warnings will not stop the submission.
- Not Using the Right Application Form: Different types of grants (with different activity codes) have different forms, and the forms can change. Make sure you are using the right one. Go to the NIH Guide to Grants and Contracts and pull up the Funding Opportunity Announcement (FOA) associated with the specific grant you want. You will be directed to the right form. Our forms are regularly updated, so don’t assume last year’s form will work!
FreeMind: The recent move to Forms-D exemplifies this point exactly. Always keep your eye open and finger on the pulse in regards to what are the correct forms.
- Not Giving the SBIR/STTR Instructions Enough Attention: They hold the keys to a successful submission and contain step-by-step guidance and specific submission and review considerations for your proposal.
FreeMind: The devil is in the details. Beyond just getting your grant in there for review technically, there’s a lot that you need to consider, plan and fret on in order to out that excellent proposal that has a chance of winning. Review considerations are a good place to start, but there are lot of informal improvement items not mentioned there.
- Producing an Incomplete Application: Including appropriate details in your research proposal is important, so make sure your final grant package has everything you need. Be sure to provide enough information in the Research Strategy section for reviewers to understand what problem you aim to solve, what experimental methods you will employ, how you plan to analyze the results, and what your milestones for success are. Also, make sure to include your budget! Applications lacking sufficient detail cannot be sent to reviewers.
FreeMind: In brief, you MUST get the reviewers enthusiastic about your work. They can’t do that if they don’t know what you’re doing, why, and how.
- Overstuffing Your Application: NIH will not let you exceed the page limit by putting important research strategy information in sections of the application that are not page-limited, such as the Vertebrate Animals or Human Subjects sections.
FreeMind: You might be tempted to put in that missing explanation on using a certain animal model tacked on with a little preliminary results you have on the model in the vertebrate Animals section. After all, 12 pages for Research Strategy is indeed very limited. Don’t do it. It’s quite possible that the reviewers will disqualify you for this.
- Submitting a New Application but Referring to Previous Review Outcomes or Criticism: Since NIH now accepts previously reviewed applications as “new,” be careful not to refer to the score of the earlier application or discuss how reviewer comments were addressed.
FreeMind: Indeed a “new” proposal is exactly that – new. It’s definitely tempting to address critiques, but leave that for resubmissions.
- Using a Small Font: NIH can withdraw your application before review if you ignore standards for font and text size. Even if we don’t withdraw such an application, reviewers will likely struggle to read your application and see its merits.
FreeMind: Always stick with the guidelines for font, margins, page limits, etc. No fooling around here. We’ve seen applications dismissed for using the wrong font type.
To summarize and conclude, there are many pitfalls and challenges in submitting a successful SBIR or STTR grant to the NIH. Some of these are indeed technical – and the CSR has mentioned some of these above. It should be noted however, that a technically fit SBIR proposal is a far cry from a winning proposal. It is defining your aims correctly, planning your endpoint milestones prudently, and many additional, non-technical but highly relevant attributes that make up a winning proposal. We will be discussing some of these in later blog entries.
Manager of Consulting Services
This video was written, produced, and narrated by our own VP, Ayal Ronen. Ayal worked closely with Wander productions to make this excellent introductory video come to light.
The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.
read more: https://grants.nih.gov/grants/guide/pa-files/PAR-14-088.html
Meet FreeMind at the Partnership in Clinical trials event in Las Vegas on March 30th to discuss sources of funding able to fund your clinical trial!
For more than 22 years, Partnerships has been a cornerstone for thousands of clinical executives to partner, learn, and innovate. This coming year, we’re taking PCT to a whole new level. Watch and let Partnerships be your main destination for productivity, meetings, and ideation in 2014.
In 2013 NIH alone awarded some $10B to clinical studies and roughly $3.5B to clinical trials, from Phase I through Phase III.
The Fiscal Year 2014 Department of Defense Appropriations Act will fund some$580,000,000 through the Congressionally Directed Medical Research Programs (CDMRP).
Programs range from Oncology, ALS, Autism, through MS, Orthopedic research and more.
Program Announcements will be issued during 2014, Stay Tuned!
The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.
Peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):
- Amyotrophic Lateral Sclerosis Research Program – $7.5 million
- Autism Research Program – $6.0 million
- Bone Marrow Failure Research Program – $3.2 million
- Breast Cancer Research Program – $120.0 million
- Duchenne Muscular Dystrophy Research Program – $3.2 million
- Gulf War Illness Research Program – $20.0 million
- Lung Cancer Research Program – $10.5 million
- Multiple Sclerosis Research Program – $5.0 million
- Neurofibromatosis Research Program – $15.0 million
- Ovarian Cancer Research Program – $20.0 million
- Peer Reviewed Cancer Research Program – $25.0 million
- Peer Reviewed Medical Research Program – $200.0 million
- Peer Reviewed Orthopaedic Research Program – $30.0 million
- Prostate Cancer Research Program – $80.0 million
- Spinal Cord Injury Research Program – $30.0 million
- Tuberous Sclerosis Complex Research Program – $6.0 million
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – October 14, 2013
CEOCFO: Mr. May-Ron, what is the vision and concept at FreeMind Group?
Mr. May-Ron: What we are trying to do is just one thing. Within the life science industry there are three main sources of funding globally as well as the US. One is private investments, the VC (Venture Capital) community and Angel Investors. Then there is the public market with the IPOs. However, the largest source of funding available to support research in the life sciences are really the non-dilutive sources. That would be the government to a great extent, with about $50 billion awarded every year in the United States from non-dilutive sources to support Research and Development. The truth is that this world is a bit misunderstood. Companies, Universities, Researchers and CEOs do not really know what is available. They do not even know how to approach and effectively get funding that they could win. It is completely non-dilutive, they pay nothing for it, no shares and that is exactly what we are trying to do. We want to help our clients get as much money as possible to support the research and development in the life sciences from such non-dilutive sources.
CEOCFO: What are some of the more simple concepts in how you go about getting funding and what might be a couple of things that FreeMind Group understands that others might not?
Mr. May-Ron: There are no magic tricks or great knowledge that we posses or special relationships. It has to do with a great deal of work. The one major factor is to understand that this must be taken seriously. Many turn automatically to the SBIR (Small Business Innovation Research) Program, which is a good program, but not necessarily the best one available. It is only 2.5% of the funding available. However, if they would know about the possibility of getting an awards from the SBIR program as well as other mechanisms to support some of their research they could increase relevant sources of funding. Most CEOs take a onetime approach, try to submit a single application and give it a chance. Usually they would not win on the first go because it does take time and an effort, but they must not give up. After fourteen years in business there are things that we have come to know. For example, taking a systematic, multi-submission, strategic approach, where you identify on a regular basis all of the different funding sources. Then make sure to match the strategic scientific needs of the company to those funding opportunities that are relevant for you in every direction that are relevant to you, from every source possible, and you can submit on a regular systematic basis. With that approach, you can increase significantly your chances of success and create a real stream of funding for your organization. A long-term systematic approach will force you to look at the Phase 2 while you write the Phase 1, because you understand that it is a longer-term process. You could also take into account other mechanisms such as an RO1 or an Army Award; it really does not matter. You need to understand every possible funding sources available and then allocate resources to get those on a systematic basis.
CEOCFO: When you are matching up people who need money and sources of money, how much is technology or how much is experience? What is the process?
Mr. May-Ron: There are two processes and that reflects the way that we are structured here at FreeMind Group. We have 40 full time employees and we are broken into two groups. A smaller group of Analysts all with PHDs, with great experience writing their own applications. Then a larger group of writers and managers who do not have PHDs, but rather Masters degrees in Life Science and MBAs, so they posses understanding of science and the tools to express and present science in a specific way. When we start working with any client, whether it is a big pharma or small start-up, large Ivy League University or independent small research institution, we start with a strategic assessment, a series of conference calls or video conferences, aimed at fully understanding our clients’ scientific strategies. We want to find out what exactly do they plan on doing and what are the milestones that they want to go through in the next 18 to 24 months. Based on that our analysts will identify every funding opportunity possible, both through the solicited sources, because about 20% to 25% of all awards are solicited and from unsolicited sources. In which case we will approach program officers and ask for their feedback on specific projects. Based on all of that information we can then present our clients with two things. Number one, is a long list of opportunities or a map of different funding sources and opportunities; very specific ones. That would include deadlines, specific dates, how much money they can get out of these specific opportunities, what is the scientific scope that we can do and what is our assessment as to their chances of being successful and awarded. Then they can choose out of these opportunities that fit their strategy. The number two thing that we will give them is a long-term multi-submission strategy. What do our analysts believe should be the path and which application should we submit first. That is the first process. Then at that point we will strategize for each specific application, which mechanism to use, how much money to ask for, what specific aim to focus on, what should be the research design and collaborators. Then we will generate a template for the application, which will be the basis for the interaction between our writing team and our clients. We will write the application together, in a joint writing process, through a ping-pong of write and rewrite. Up to the point of submission we will cover every aspect of it: scientific, clinical, financial, administrative and resources. Every aspect of the application we will be able to cover and relate both the needs of the funding institute that we discussed earlier and the strategy of the application itself and its focus on the company needs. In this way we are trying to match not only the specific needs but also the presentation of science to the specific opportunity and institute that may give it the funding and to the needs of the company.
CEOCFO: When you are speaking with the CEO of a company; it may be a smaller one where funds may be tight; what is the “aha” moment when they understand that they should be spending dollars to get more potential funding?
Mr. May-Ron: The “aha” moment occurs when you tell them that within the past three years, each and every year NIH and DoD have invested or awarded more money to life science companies, compared to the entire VC community. When you understand that NIH and DoD give more money than the VC community. However, it is just as hard, it is not easy, but it is a very large sum of money that is available. That is the point that they realize that this is something should be taken seriously.
CEOCFO: Why do you think that so many people in the research and development community have not realized this?
Mr. May-Ron: It is a misperception that we have been fighting against for many years. It is derived from their academic backgrounds. Many researchers leave academia not to deal any more with writing grants and applications. There were more easier ways of getting funding, but the atmosphere and market has changed. It is not as easy to get funding from VCs anymore. They do not really present that great opportunity that they used to present. Individual angel investors do not really get there. At the same time, NIH and DoD are taking a huge leap towards industry. Today there is a great deal more money directed towards translational and clinical programs; not only basic research. Therefore, there is a gap of understanding of the needs, purpose and interests of these funding sources and how they may relate to the company’s needs. Many researchers and CEOs that I speak with, when I tell them that they can apply for an RO1, they think that it is just for Universities. However, if you go through the NIH website and look up the numbers you will see that many companies have won RO1s and R21s.
CEOCFO: How do you reach perspective clients?
Mr. May-Ron: We reach perspective clients mainly through the many activities that we do, such as educational work. We just held a weekly summer school. A series webinars during July and August, where we had about 100 to 200 attendees every week dealing with different aspects of approaching identifying and writing applications. It is all free. We have our annual event that we conduct adjacent to the JP Morgan event in January in San Francisco. This coming January will be the 9th annual event that we hold. Every year we have great speakers and workshops that we conduct free of charge. Beyond that we attend conferences and we meet people. These are standard ways of getting in front of people.
CEOCFO: Is there much competition or any companies that specialize the way that you do?
Mr. May-Ron: There are two different levels. When you talk about academia the main competition is internal, because every university has a grants office. They do not necessarily do what we do, and very few do that, but we work with many universities as well as many academic research institutes. We work together with these grants offices, but in theory they do present a competition. When you go into the industry mainly one can find many individual consultants focusing mainly on the SBIR Program; nothing beyond that and definitely no one our size. Therefore, there is a little bit of competition, but not very significant.
CEOCFO: You have an office in Israel; is the international arena a growing area for you?
Mr. May-Ron: About 15% to 20% of our work today is with non-American clients, such as in Germany, Austria, Spain, France, the UK. All over Europe. In fact, I will be in Vienna in November. We also have clients in Canada and Israel as well as Australia and Singapore. Therefore, we have many international clients and the key issue is the fact that most of the American non-dilutive sources programs are not discriminating against non-Americans winning. Hence, it is just as hard and very competitive. It is difficult to get the funding. Being a non-American company such as a Canadian company is not going to prevent you from winning. The question is going to be scientific. For those companies and universities around the world, this is a great achievement. Not only financially to get funding from the NIH, but also the recognition, approved and awarded by the top researchers and institutes in the world. That is of great significance for the money, but not only the money. With exception to the SBIR Program, these are only for Americans. Most of the other mechanisms will allow non-Americans.
CEOCFO: Are there concerns over funding with the US government crisis looming?
Mr. May-Ron: It is a concern, but it is not a major one. I do not think anything is dramatically different from what we experienced October 2012. There were government shut downs under previous administrations, so there is nothing amazingly new. If we look at the budget itself, it is quite evident that there has not been any major increases in NIH and DoD in life science research budget on the one hand. But on the other hand there has not been any major cutoffs either. For the individual company asking for example a $2 million award for whatever specific research you need to conduct, whether the NIH will have a budget of $30.9 billion or $29.7 billion will not make that much of a difference for the particular application. Therefore, there should not be a direct impact. However, CEOs should not just look into one source of funding; dilutive and non-dilutive funding to complement each other and get as much funding for the organization as they could.
CEOCFO: The VC community tends to be cyclical not just the amounts of money; certain conditions or areas are in favor and other times are not. Do you find the same situation in the grant area?
Mr. May-Ron: They are definitely broader. You have funding going to support anything that is remotely life sciences oriented from healthcare IT to nursing or behavioral research, development new technologies and medical devices to a new treatment for cancer or flu vaccine. Basic research all the way to Phase III. The fact that NIH supports cancer research in over $6 billion every year is true, but within that great field of cancer research there are specifics and if they have funded seven such projects of a particular focus last year, they may not fund very many in that area this year. Therefore, you have to be aware of all of these facts. It is harder because while the VCs will shift altogether towards one end, here you would have specific institutes and specific mechanisms that will make those shifts. Sometimes it may go in opposite directions. Therefore, you need to approach these organizations and fully understand their interests and their focus, so that you can address those issues. It is just like any other selling proposition. Without knowing the audience, it is difficult to make a sale.
CEOCFO: What should investors and people in the business community pay attention to FreeMind Group?
Mr. May-Ron: People should not necessarily pay attention to FreeMind Group. They should pay attention to non-dilutive sources of funding within the life sciences. We submit about 300 applications per year. Yes, we are large, successful and strategic and I definitely believe that we can help every client that we work with, but I am bias. If companies would accept the sources of funding that are crucial to the industry and that are the largest available part of this money, it will help the industry at large. Some will fail and some will succeed, but that is ok. But mainly people need to recognize this amazing and huge source of funding and treat it seriously.
The 2013 Galien Forum will take place at the Alexandria Center for Life Science on the morning of October 22nd, 2013, and will feature round table debates focusing on critical global healthcare issues and challenges.
The annual life science Forum is rapidly becoming a leading event for discussing issues of innovation in the industry. The Galien Forum brings together leading CEOs, biomedical experts from industry, academia and government.
4th GALIEN FORUM
Alexandria Center™ for Life Science –
450 East 29th Street, 2nd Floor
(between 1st Avenue and the East River)
New York City -7:30 AM- 4:00 PM
The National Science Foundation (NSF) has recently updated the SBIR and STTR programs for the upcoming December 2nd and 4th deadlines, respectively. Areas of interest cover Biological and Biomedical Technologies and are a fantastic source of funding for early-stage projects. Some $42,000,000 will be awarded through these mechanisms to roughly 250 awards.
ABOUT THE NSF
The National Science Foundation is an independent federal agency created “to promote the progress of science; to advance the national health, prosperity, and welfare; to secure the national defense…” With an annual budget of about $7.0 billion (FY 2012), The NSF is a funding source for approximately 20 percent of all federally supported basic research conducted by America’s colleges and universities. In many fields such as mathematics, computer science and the social sciences, NSF is the major source of federal backing.
– TOPICS OF INTEREST –
BIOLOGICAL TECHNOLOGIES (BT)
BT1. Agricultural and Food Security Biotechnology. New approaches for meeting the world’s future nutritional needs. Target areas for improvement may include (but are not limited to) drought tolerance, improved nutritional value, enhanced disease resistance, and higher yield. Proposers should give consideration to technologies that enhance biodiversity, produce less carbon dioxide, and use less water and fertilizer.
BT2. Biosensors. Biosensors are sensorsthat contain a biologically-based sensing element. Proposed projects might include (but are not limited to) real-time sensors, microbial component-based sensors, sensors for monitoring fluxes of metabolites, nanobiotechnology-based sensors, biomedical sensors, and micro- or nanofluidic-based sensors. Application areas of interest may include (but are not limited to) toxicity testing, food safety, drug evaluation, environmental monitoring, and bio-prospecting. Other types of sensors should refer to the EI topic.
BT3. Life Sciences Research Tools. Developing novel technologies that will advance scientific research across the biological spectrum. This may include enabling technologies for drug discovery (high-throughput screening assays and platforms, and high-content screening assays and platforms; novel high-content screening technologies based on characterization of physical properties of cells are of high interest). Proposals should focus primarily on the development of innovative consumables, processes, and services where there is significant market opportunity.
BT4. Bioinstrumentation. The development of technology for novel or improved instrumentation primarily for biological research applications.
BT5. Synthetic Biology and Metabolic Engineering. Using synthetic biology to engineer novel biologically-based (or inspired) functions that do not exist in nature. Proposed projects may include creating new manufacturing capability by designing microorganisms, plants, and cell-free systems for the production of novel chemicals and biomolecules. Applications may include (but are not limited to) health-care products, food ingredients, chemicals, and other biomaterials such as enzymes and bio-based polymers.
BIOMEDICAL TECHNOLOGIES (BM)
BM1. Pharmaceutical Manufacturing. Proposed projects must include new processing or manufacturing devices, components, and systems that will improve the efficiency, competitiveness, and output of the nation’s pharmaceutical manufacturing sector; that will reduce the cost, risk, and time-to-market of new pre-clinical and clinical-stage drugs and biological products; or that address major market opportunities in the developing world. Proposed projects may include transformative approaches and methods in manufacturing operations, project management, process development, process engineering, analytical development, or quality control and assurance. Proposals are strongly encouraged to address the net preservation and extension of natural resources, a reduction in the use or release of toxic or harmful constituents, the use of less extreme temperatures or conditions, or a reduction in the production of waste.
BM2. Materials for Biomedical Applications. Proposed projects may include biological materials, biomimetic, bioinspired, bioenabled materials and synthetic materials, all intended for biological, medical, veterinary, or healthcare applications. Examples of proposals may include (but are not limited to) the synthesis, purification, functionalization, characterization, development, validation, processing, scale up, and manufacturing of biomaterials. Novel polymeric materials, polymers, plastics, additives, sealants, elastomers, textiles, alloys, ceramic and composite biomaterials, improved implants; coatings for therapeutic applications; or nanomaterials.
BM3. Tissue Engineering and Regenerative Medicine. Proposed projects may include enabling engineering and manufacturing approaches, technologies and systems that will advance the research, development, quality control, and production of artificial tissues and their derivatives in scientific, therapeutic, or commercial applications. Proposed projects may also include novel methods or technologies to replace or regenerate damaged or diseased animal or human cells, tissues, or organs to restore or establish their normal function.
M4. Biomedical Engineering. Proposed project should focus on using engineering approaches to develop transformative methods and technologies that will solve problems in medicine. Proposed projects may include devices and systems that provide new strategies for the prevention, diagnosis, and treatment of health conditions; advance end of life or palliative care; reduce drug counterfeiting; and enable new and more efficient risk-management methods to better address safety issues of drugs and medical devices; motion or structural biomechanic technologies for the improvement of human motion, and sensors, actuators, and intelligent systems for surgical robotics. Proposers are encouraged to form an interdisciplinary team that includes relevant engineering as well as biology/health-related expertise.
BM5. Medical Imaging Technologies. Proposed projects may include (but are not limited to) novel or improved imaging technologies and/or imaging agents to advance the diagnosis and treatment of disease , and improve prognosis.
BM6. Diagnostic Assays and Platforms. Proposed projects should focus on transformational diagnostic technologies. Proposed projects may include (but are not limited to) non- or minimally-invasive disease diagnosis, detection and monitoring, software-based diagnostic methods, biomarker development, disease-specific assays, personalized medicine, flexible implantable devices, lab-on-a-chip technologies, and low-cost point-of-care testing for diseases.
BM7. Drug Delivery. Proposed projects may include novel and transformative platforms, chemical formulations, excipients, devices, or methodology for the delivery of drugs or biological products.
BT6. Fermentation and Cell Culture Technologies. Proposed projects might include (but are not limited to) novel or improved microbial fermentation or mammalian and plant cell culture technologies, bioreactors, processes, scale-up, development of expression platforms, and purification.
BT7. Computational Biology and Bioinformatics. Developing and applying computationally intensive techniques (e.g., pattern recognition data mining, machine learning algorithms, and visualization) and may include (but are not limited to) sequence alignment, gene finding, genome assembly, drug design, drug discovery, protein structure alignment, protein structure prediction, prediction of gene expression and protein-protein interactions, genome-wide association studies, and the modeling of evolution. Proposed projects might include the creation and advancement of databases, algorithms, computational and statistical techniques, and theory to solve problems arising from the management and analysis of biological data.
Pumping Congress to find a way to wipe away the sequester cuts, or at the very least exempt NIH or restore funding another way, has become an important part of NIH Director Francis Collins’ job, which also includes singing the blues about the sequestration.
Collins says he has probably personally visited with more than 100 members of Congress in the last year, at NIH’s headquarters or down on Capitol Hill, as part of his campaign to combat sequestration.
He says it doesn’t matter which party he meets with on the Hill, they agree that the NIH funding cuts should be done away with. But then they tell him that there is nothing they can do, because of the “national impasse” over government spending and the deficit.